Journal
BIOFACTORS
Volume 32, Issue 1-4, Pages 151-159Publisher
WILEY
DOI: 10.1002/biof.5520320118
Keywords
Breast cancer; Tamoxifen; Coenzyme Q(10); angiogenesis; hypolipidemia; tumour markers
Ask authors/readers for more resources
Tamoxifen, a non-steroidal anti-estrogen is now widely used and has led to an increase in both disease-free and overall survival of women after primary surgery. Tamoxifen therapy is found to cause hypertriglyceridemia by reducing activity of lipolytic enzymes on triglycerides, and thereby increasing the risk of cardiovascular disease. Angiogenesis promotes local tumour progression and invasion and enables tumour cell dissemination and metastasis formation. Our study has found that co-administration of Coenzyme Q(10) (100 mg) along with tamoxifen (10 mg, twice a day) to breast cancer patients reduced the level of angiogenesis markers and lipid levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available